Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Irvine › NPI 1427658848
Lab

Breakthrough Genomics INC

Breakthrough Genomics INC was paid $2.30M by Medicaid between Jan 2021 and Sep 2024, across 4 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 71% of everything it billed.

33Billing provider infoBREAKTHROUGH GENOMICS INC
IRVINE, CA 92618
33aNPI1427658848assigned 10/26/2020
28Total paid$2.30M
24GClaims63,227
24DCodes billed4
24AFirst – last monthJan 2021 – Sep 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#140 of 561
Median peer was paid$222K
This provider vs. median10×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$100K$200K$300K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
202118,530$562K
202236,811$1.41M
20237,311$312K
2024incomplete575$16K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 71% 27,507 10,143 $1.64M
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 16% 20,472 7,684 $371K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 11% 14,539 5,301 $264K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 709 276 $22K

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLI, WENHUI (PRESIDENT & CEO)